

Title:

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Investigators:

- Dr Steven Zizzo, Winterberry Clinical Research
- Dr John O'Mahony, Bluewater Clinical Research Group

Description of the Study:

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last approximately 9 months.

Funding Source:

Sponsored by Eli Lilly

Project Start Date: March 28, 2025

Project End Date: January 1, 2027

Inclusion Criteria:

- Have type 2 diabetes
- Have HbA1c $\geq 7.5\%$ to $\leq 10.5\%$ at screening
- Have a body mass index (BMI) of ≥ 27 kilograms per square meter (kg/m²) at screening
- Have had a stable body weight for the three months prior to screening
- On stable treatment dose of one of the following incretins for at least three months prior to screening:
 - Injectable semaglutide (1 and 2 milligram (mg))
 - Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg)

Ethics Approval:

Advarra IRB Protocol ID #Pro00084681

Participation:

The experimental medication or placebo will be administered via subcutaneous injection. Participation in the study will last about 9 months. Over this period, participants will complete 11 in-person visits at the research site, and one virtual/phone visit.

There are two research sites participating in this trial. Interested participants should contact one of the sites below.

- For Bluewater Clinical Research Group located in Sarnia, ON:
 - Call (519) 344 6612
 - Email info@bwresearch.ca
 - Visit www.bwresearch.ca
- For Winterberry Medical Clinic located in Hamilton, ON:
 - Call (365) 366 6267
 - Email research@winterberrymedical.ca
 - Visit <https://www.winterberrymedical.ca/research/>

Subjects are informed of the known trial risks and benefits before the trial starts, also known as informed consent. Subjects can withdraw from a trial at any time, for any reason.

Website:

- <https://www.winterberrymedical.ca/2024/12/26/transforming-lives-through-diabetes-research/>
- <https://www.bwresearch.ca/studies/t2dm>
- <https://joinastudy.ca/current-studies/study-for-participants-with-type-2-diabetes-on-a-stable-dose-of-semaglutide-or-tirzepatide/>